{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:04:55Z","timestamp":1778839495697,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.chest.2017.05.018","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T13:03:41Z","timestamp":1496235821000},"page":"339-348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["CA-125 in Disease Progression and Treatment of Lymphangioleiomyomatosis"],"prefix":"10.1016","volume":"153","author":[{"given":"Connie G.","family":"Glasgow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Pacheco-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy K.","family":"Steagall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E.","family":"Haughey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia A.","family":"Julien-Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario P.","family":"Stylianou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadette R.","family":"Gochuico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Moss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.chest.2017.05.018_bib1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/CLEP.S50780","article-title":"Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis","volume":"7","author":"Taveira-DaSilva","year":"2015","journal-title":"Clin Epidemiol"},{"issue":"suppl 1","key":"10.1016\/j.chest.2017.05.018_bib2","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.rmed.2010.03.017","article-title":"Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies","volume":"104","author":"Glasgow","year":"2010","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2017.05.018_bib3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.chest.2017.05.018_bib4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1165\/rcmb.2005-0300OC","article-title":"Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: role for tumor suppressor TSC2","volume":"34","author":"Goncharova","year":"2006","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"11","key":"10.1016\/j.chest.2017.05.018_bib5","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nrd3531","article-title":"Rapamycin passes the torch: a new generation of mTOR inhibitors","volume":"10","author":"Benjamin","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"17","key":"10.1016\/j.chest.2017.05.018_bib6","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.chest.2017.05.018_bib7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.chest.2017.05.018_bib8","doi-asserted-by":"crossref","first-page":"797","DOI":"10.7326\/0003-4819-154-12-201106210-00007","article-title":"Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus","volume":"154","author":"Taveira-DaSilva","year":"2011","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.chest.2017.05.018_bib9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1164\/ajrccm.186.4.389","article-title":"Resolution of chylous pulmonary congestion and respiratory failure in LAM with sirolimus therapy","volume":"186","author":"Moua","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2017.05.018_bib10","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1172\/JCI110380","article-title":"Reactivity of a monoclonal antibody with human ovarian carcinoma","volume":"68","author":"Bast","year":"1981","journal-title":"J\u00a0Clin Invest"},{"issue":"10","key":"10.1016\/j.chest.2017.05.018_bib11","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1096\/fj.14-257352","article-title":"MUC16: molecular analysis and its functional implications in benign and malignant conditions","volume":"28","author":"Haridas","year":"2014","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.chest.2017.05.018_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1095\/biolreprod.106.058347","article-title":"MUC16 is lost from the uterodome (pinopode) surface of the receptive human endometrium: in\u00a0vitro evidence that MUC16 is a barrier to trophoblast adherence","volume":"78","author":"Gipson","year":"2008","journal-title":"Biol Reprod"},{"issue":"6","key":"10.1016\/j.chest.2017.05.018_bib13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/biof.64","article-title":"Current status of mucins in the diagnosis and therapy of cancer","volume":"35","author":"Rachagani","year":"2009","journal-title":"Biofactors"},{"issue":"10","key":"10.1016\/j.chest.2017.05.018_bib14","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1167\/iovs.07-0430","article-title":"Functions of MUC16 in corneal epithelial cells","volume":"48","author":"Blalock","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.chest.2017.05.018_bib15","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1096\/fj.08-119131","article-title":"Characterization of exosome-like vesicles released from human tracheobronchial ciliated epithelium: a possible role in innate defense","volume":"23","author":"Kesimer","year":"2009","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.chest.2017.05.018_bib16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2003.12.043","article-title":"The predictive and prognostic value of serum CA 125 half-life during paclitaxel\/platinum-based chemotherapy in patients with advanced ovarian carcinoma","volume":"93","author":"Gadducci","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.chest.2017.05.018_bib17","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.7314\/APJCP.2013.14.6.3937","article-title":"Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer","volume":"14","author":"Zhang","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"10.1016\/j.chest.2017.05.018_bib18","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.cllc.2011.03.019","article-title":"Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC)","volume":"12","author":"Cedres","year":"2011","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"10.1016\/j.chest.2017.05.018_bib19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.5468\/ogs.2013.56.5.281","article-title":"Predictive value of preoperative serum CA-125 levels in patients with uterine cancer: the Asian experience 2000 to 2012","volume":"56","author":"Patsner","year":"2013","journal-title":"Obstet Gynecol Sci"},{"issue":"1","key":"10.1016\/j.chest.2017.05.018_bib20","first-page":"145","article-title":"Preoperative serum tumor marker levels in gastric cancer","volume":"30","author":"Polat","year":"2014","journal-title":"Pak J Med Sci"},{"issue":"6","key":"10.1016\/j.chest.2017.05.018_bib21","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1378\/chest.126.6.1867","article-title":"Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone","volume":"126","author":"Taveira-DaSilva","year":"2004","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2017.05.018_bib22","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.ajpath.2013.05.024","article-title":"Osteoprotegerin contributes to the metastatic potential of cells with dysfunctional TSC2 tumor suppressor gene","volume":"183","author":"Steagall","year":"2013","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.chest.2017.05.018_bib23","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1378\/chest.10-0573","article-title":"Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases","volume":"138","author":"Young","year":"2010","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.chest.2017.05.018_bib24","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2213-2600(13)70090-0","article-title":"Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial","volume":"1","author":"Young","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.chest.2017.05.018_bib25","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1165\/ajrcmb.21.3.3693","article-title":"Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis","volume":"21","author":"Matsumoto","year":"1999","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"2","key":"10.1016\/j.chest.2017.05.018_bib26","first-page":"866","article-title":"Immunohistochemical localization of placental alkaline phosphatase, carcinoembryonic antigen, and cancer antigen 125 in normal and neoplastic human lung","volume":"46","author":"Nouwen","year":"1986","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.chest.2017.05.018_bib27","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1378\/chest.14-0380","article-title":"Antibody \u03b1PEP13h reacts with lymphangioleiomyomatosis cells in lung nodules","volume":"147","author":"Valencia","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.chest.2017.05.018_bib28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1476-4598-13-129","article-title":"MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress","volume":"13","author":"Felder","year":"2014","journal-title":"Molecular Cancer"},{"issue":"4","key":"10.1016\/j.chest.2017.05.018_bib29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1530\/ERC-15-0505","article-title":"Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model","volume":"23","author":"Prizant","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.chest.2017.05.018_bib30","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1165\/rcmb.2008-0335OC","article-title":"The loss of tuberin promotes cell invasion through the \u03b2-catenin pathway","volume":"43","author":"Barnes","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"9","key":"10.1016\/j.chest.2017.05.018_bib31","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0046-8177(97)90061-7","article-title":"Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM)","volume":"28","author":"Hayashi","year":"1997","journal-title":"Hum Pathol"},{"issue":"10","key":"10.1016\/j.chest.2017.05.018_bib32","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.chest.2017.05.018_bib33","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/srep01870","article-title":"Mesothelin binding to CA125\/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation","volume":"3","author":"Chen","year":"2013","journal-title":"Sci Rep"},{"issue":"pt 7","key":"10.1016\/j.chest.2017.05.018_bib34","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1242\/jcs.00312","article-title":"The cancer antigen CA125 represents a novel counter receptor for galectin-1","volume":"116","author":"Seelenmeyer","year":"2003","journal-title":"J\u00a0Cell Sci"},{"issue":"5","key":"10.1016\/j.chest.2017.05.018_bib35","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/bjc.2013.828","article-title":"Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF\/mTOR signaling axis","volume":"110","author":"White","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.chest.2017.05.018_bib36","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-94-017-7215-0_14","article-title":"The role of CA 125 as tumor marker: biochemical and clinical aspects","volume":"867","author":"Bottoni","year":"2015","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"10.1016\/j.chest.2017.05.018_bib37","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1006\/gyno.2000.5776","article-title":"Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids","volume":"77","author":"Sevinc","year":"2000","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.chest.2017.05.018_bib38","first-page":"737","article-title":"The ovarian cancer associated antigen CA 125 in\u00a0patients with pleural effusions","volume":"24","author":"Lindgren","year":"1988","journal-title":"Eur\u00a0J\u00a0Cancer Clin Oncol"},{"issue":"2","key":"10.1016\/j.chest.2017.05.018_bib39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/1097-0142(19870115)59:2<213::AID-CNCR2820590206>3.0.CO;2-I","article-title":"Elevation of CA 125 in patients with benign and malignant ascites","volume":"59","author":"Bergmann","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.chest.2017.05.018_bib40","first-page":"47","article-title":"Highly elevated serum CA 125 in a lady with ascites and retroperitoneal mass\u2014a diagnostic dilemma","volume":"56","author":"Hazarika","year":"2008","journal-title":"JAPI"},{"issue":"1","key":"10.1016\/j.chest.2017.05.018_bib41","article-title":"Chylous ascites caused by sarcoidosis","volume":"38","author":"Mak","year":"2002","journal-title":"Hospital Physician"},{"issue":"6","key":"10.1016\/j.chest.2017.05.018_bib42","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/j.1572-0241.1999.01152.x","article-title":"Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis","volume":"94","author":"Zuckerman","year":"1999","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.chest.2017.05.018_bib43","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.resinv.2013.03.002","article-title":"The efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis","volume":"51","author":"Ando","year":"2013","journal-title":"Respir Investig"},{"issue":"5","key":"10.1016\/j.chest.2017.05.018_bib44","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1378\/chest.08-1160","article-title":"Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement","volume":"135","author":"Glasgow","year":"2009","journal-title":"Chest"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369217310188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369217310188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T07:59:30Z","timestamp":1757923170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369217310188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0012369217310188"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2017.05.018","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CA-125 in Disease Progression and Treatment of Lymphangioleiomyomatosis","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2017.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}